<?xml version="1.0" encoding="UTF-8"?>
<ref id="B37-ijerph-17-04951">
 <label>37.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Grebely</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Hajarizadeh</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Lazarus</surname>
    <given-names>J.V.</given-names>
   </name>
   <name>
    <surname>Bruneau</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Treloar</surname>
    <given-names>C.</given-names>
   </name>
   <collab>International Network on Hepatitis in Substance Users</collab>
  </person-group>
  <article-title>Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all</article-title>
  <source>Int. J. Drug Policy</source>
  <year>2019</year>
  <volume>72</volume>
  <fpage>1</fpage>
  <lpage>10</lpage>
  <pub-id pub-id-type="doi">10.1016/j.drugpo.2019.07.016</pub-id>
  <pub-id pub-id-type="pmid">31345644</pub-id>
 </element-citation>
</ref>
